News

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.
The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...
OVER 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine. The UK ...
Arexvy is not used in the NHS but may be accessed privately by adults over 60, or those aged 50-59 at higher risk. Arexvy is not recommended for use in pregnancy. However, ...
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...
It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant stimulates cells of the immune system that could help protect the brain ...
A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...
Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...
A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...
Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations face rising infection risks.